D-0655-2021 Class III Terminated

Recalled by Partner Therapeutics Inc — Lynnwood, WA

FDA drug recall D-0655-2021 was initiated by Partner Therapeutics Inc on Jun 23, 2021 and is designated Class III. Reason for recall: FAILED STABILITY SPECIFICATION: Out-of-specification (OOS) result observed for Leukine (sargramostim) at the 27-month stability timepoint. The recall status is terminated (terminated Feb 7, 2023). Affected quantity: 32,260 vials.

Recall details

Product Type
Drugs
Report Date
Jul 21, 2021
Initiation Date
Jun 23, 2021
Termination Date
Feb 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
32,260 vials

Product description

LEUKINE (Sargramostim) for Injection, 250 mcg/ vial, 5mL vials, 5 (250 mcg vials) per box, Rx only, Mfd by Partner Therapeutics, Inc. Lexington, MA 02421, NDC 71837-5843-5

Reason for recall

FAILED STABILITY SPECIFICATION: Out-of-specification (OOS) result observed for Leukine (sargramostim) at the 27-month stability timepoint.

Distribution pattern

Product was distributed to one government account (ASPR)

Code information

Lot #: E8023E, exp. date 11/30/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0655-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0655-2021. Report a data issue: hello@regdatalab.com.